http://www.ajo.com/article/S0002-9394(09)00410-3/abstract

This study looked at the the effect of intravitreal bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) on visual acuity and macular thickness in patients with inflammatory choroidal neovascularization (CNV) or cystoid macular edema (CME).

The study concluded that Bevacizumab appears to stabilize the eyes with inflammatory choroid neovascularisation or cystoid macula edema.

This type of treatment is only available in the UK on the NHS for people who have wet AMD. If it does help people with choroidal neovascularization (CNV) or cystoid macular edema (CME), (possible complications of birdshot chorioretinoapthy), as this research would indicate, we need to take action and lobby for it as a possible treatment.